Table 1.
Current clinical trials combining Wnt inhibitor and immune checkpoint inhibitor.
| Drug | ICI Agent | Mechanism of Action of Wnt Inhibitor | Disease | Clinical Trial | Trial Phase |
|---|---|---|---|---|---|
| LGK974 | PDR001 (anti-PD-1) | PORCN inhibitor | Solid tumors | NCT01351103 | Phase I |
| ETC-1922159 | pembrolizumab (anti-PD-1) | PORCN inhibitor | Solid tumors | NCT02521844 | Phase IA/B |
| CGX1321 | pembrolizumab (anti-PD-1) | PORCN inhibitor | Advanced GI Tumors | NCT02675946 | Phase I/Ib |
| DKN-01 | nivolumab (anti-PD-1) | DKK1 inhibitor | Advanced Biliary Tract Cancer | NCT04057365 | Phase II |
| DKN-01 ± chemotherapy | tislelizumab (anti-PD-1) | DKK1 inhibitor | Advanced Esophagogastric Cancer | NCT04363801 | Phase IIa |
| DKN-01 | pembrolizumab (anti-PD-1) | DKK1 inhibitor | Advanced Esophagogastric Cancer | NCT02013154 | Phase I |